menu
    • menu

    Find MDL-101 manufacturers, exporters & distributors on PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    0

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    0

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    0

    API

    0

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    0

    FDF Dossiers

    FDF Dossiers

    0

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    3DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    1

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    NA

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Mdl-101628, Mdl 101628, Mdl-101,628, 142589-11-5, Pyrido(2,1-a)(2)benzazepine-4-carboxylic acid, 1,2,3,4,6,7,8,12b-octahydro-7-(((2r)-2-mercapto-1-oxo-3-phenylpropyl)amino)-6-oxo-, (4s,7s,12br)-
    Molecular Formula
    C24H26N2O4S
    Molecular Weight
    438.5  g/mol
    InChI Key
    RIWRWPXUDHZKIO-JSXRDJHFSA-N
    MDL-101
    1 2D Structure

    MDL-101

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (4S,7S,12bR)-6-oxo-7-[[(2R)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid
    2.1.2 InChI
    InChI=1S/C24H26N2O4S/c27-22(21(31)13-15-7-2-1-3-8-15)25-18-14-16-9-4-5-10-17(16)19-11-6-12-20(24(29)30)26(19)23(18)28/h1-5,7-10,18-21,31H,6,11-14H2,(H,25,27)(H,29,30)/t18-,19+,20-,21+/m0/s1
    2.1.3 InChI Key
    RIWRWPXUDHZKIO-JSXRDJHFSA-N
    2.1.4 Canonical SMILES
    C1CC2C3=CC=CC=C3CC(C(=O)N2C(C1)C(=O)O)NC(=O)C(CC4=CC=CC=C4)S
    2.1.5 Isomeric SMILES
    C1C[C@@H]2C3=CC=CC=C3C[C@@H](C(=O)N2[C@@H](C1)C(=O)O)NC(=O)[C@@H](CC4=CC=CC=C4)S
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Mdl 100,173

    2. Mdl 100173

    3. Mdl 101,628

    4. Mdl 101628

    5. Mdl-100,173

    6. Mdl-100173

    7. Mdl-101,628

    8. Mdl-101628

    2.2.2 Depositor-Supplied Synonyms

    1. Mdl-101628

    2. Mdl 101628

    3. Mdl-101,628

    4. 142589-11-5

    5. Pyrido(2,1-a)(2)benzazepine-4-carboxylic Acid, 1,2,3,4,6,7,8,12b-octahydro-7-(((2r)-2-mercapto-1-oxo-3-phenylpropyl)amino)-6-oxo-, (4s,7s,12br)-

    2.3 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 438.5 g/mol
    Molecular Formula C24H26N2O4S
    XLogP33.5
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count5
    Exact Mass438.16132849 g/mol
    Monoisotopic Mass438.16132849 g/mol
    Topological Polar Surface Area87.7 Ų
    Heavy Atom Count31
    Formal Charge0
    Complexity681
    Isotope Atom Count0
    Defined Atom Stereocenter Count4
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Modalis Receives Rare Pediatric Designation for MDL-101 in Congenital Muscular Dystrophy

    Details:

    MDL-101 is an experimental, epigenetic editing therapy, which is under investigation in the early-stage clinical trial studies for the treatment of LAMA2-congenital muscular dystrophy.


    Lead Product(s): MDL-101

    Therapeutic Area: Rare Diseases and Disorders Brand Name: MDL-101

    Study Phase: PreclinicalProduct Type: Cell and Gene therapy

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 30, 2024

    blank

    01

    Modalis Therapeutics

    U.S.A
    arrow
    American Pharma Summit
    Not Confirmed

    Modalis Therapeutics

    U.S.A
    arrow
    American Pharma Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MDL-101

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Modalis Receives Rare Pediatric Designation for MDL-101 in Congenital Muscular Dystrophy

    Details : MDL-101 is an experimental, epigenetic editing therapy, which is under investigation in the early-stage clinical trial studies for the treatment of LAMA2-congenital muscular dystrophy.

    Brand Name : MDL-101

    Molecule Type : Cell and Gene therapy

    Upfront Cash : Not Applicable

    September 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Modalis Reports Data on MDL-101 Epigenome Editing for LAMA2-CMD Treatment

    Details:

    MDL-101 is an experimental, epigenetic editing therapy, which is under investigation in the early-stage clinical trial studies for the treatment of LAMA2-congenital muscular dystrophy.


    Lead Product(s): MDL-101

    Therapeutic Area: Rare Diseases and Disorders Brand Name: MDL-101

    Study Phase: PreclinicalProduct Type: Cell and Gene therapy

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 07, 2024

    blank

    02

    Modalis Therapeutics

    U.S.A
    arrow
    American Pharma Summit
    Not Confirmed

    Modalis Therapeutics

    U.S.A
    arrow
    American Pharma Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MDL-101

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Modalis Reports Data on MDL-101 Epigenome Editing for LAMA2-CMD Treatment

    Details : MDL-101 is an experimental, epigenetic editing therapy, which is under investigation in the early-stage clinical trial studies for the treatment of LAMA2-congenital muscular dystrophy.

    Brand Name : MDL-101

    Molecule Type : Cell and Gene therapy

    Upfront Cash : Not Applicable

    May 07, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines for the Treatment of a Type of Muscular...

    Details:

    MDL-101, an experimental, epigenetic modulation therapy, in preclinical data it supported durability and efficacy of a differentiated precision medicine approached for Congenital Muscular Dystrophy type 1a.


    Lead Product(s): MDL-101

    Therapeutic Area: Rare Diseases and Disorders Brand Name: MDL-101

    Study Phase: PreclinicalProduct Type: Cell and Gene therapy

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 20, 2022

    blank

    03

    Modalis Therapeutics

    U.S.A
    arrow
    American Pharma Summit
    Not Confirmed

    Modalis Therapeutics

    U.S.A
    arrow
    American Pharma Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MDL-101

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modula...

    Details : MDL-101, an experimental, epigenetic modulation therapy, in preclinical data it supported durability and efficacy of a differentiated precision medicine approached for Congenital Muscular Dystrophy type 1a.

    Brand Name : MDL-101

    Molecule Type : Cell and Gene therapy

    Upfront Cash : Not Applicable

    April 20, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search